Chen Wang
Impact in
- Infectious Diseases top 0.05%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Modeling and Simulation top 0.1%
- COVID-19 epidemiological studies
Papers in
-
- Chronic Obstructive Pulmonary Disease (COPD) Research 82
- Pulmonary Hypertension Research and Treatments 55
- Respiratory Support and Mechanisms 34
- Physiology 75
- Smoking Behavior and Cessation 27
- Asthma and respiratory diseases 24
- Co-authors
- Peter Horby (4 shared papers)George Fu Gao (1 shared paper)Frederick G. Hayden (1 shared paper)Simiao Chen (31 shared papers)Till Bärnighausen (22 shared papers)Juntao Yang (14 shared papers)Weizhong Yang (8 shared papers)Hua “Linda” Cai (7 shared papers)
- Journals
- The Lancet (18 papers)CHEST Journal (12 papers)International Journal of COPD (9 papers)European Respiratory Journal (9 papers)Respiratory Medicine (7 papers)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Chen Wang
543 papers receiving 30.3k citations
Chen Wang's Hit Papers
Peers
Comparison fields: 5 of 220
- Infectious Diseases 8.8k
- Modeling and Simulation 1.5k
- Pulmonary and Respiratory Medicine 6.8k
- Neurology 3.0k
- Internal Medicine 438
Countries citing papers authored by Chen Wang
This map shows the geographic impact of Chen Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chen Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chen Wang more than expected).
Fields of papers citing papers by Chen Wang
This network shows the impact of papers produced by Chen Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chen Wang. The network helps show where Chen Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Chen Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 571 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A novel coronavirus outbreak of global health concern Hit paper breakdown → | 2020 | 5555 |
| 2 | A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 Hit paper breakdown → | 2020 | 4028 |
| 3 | Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Hit paper breakdown → | 2020 | 2707 |
| 4 | Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study Hit paper breakdown → | 2018 | 1209 |
| 5 | Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension Hit paper breakdown → | 2013 | 1069 |
| 6 | COVID-19 control in China during mass population movements at New Year Hit paper breakdown → | 2020 | 613 |
| 7 | Prevalence of Chronic Obstructive Pulmonary Disease in China Hit paper breakdown → | 2007 | 611 |
| 8 | Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050 Hit paper breakdown → | 2023 | 566 |
| 9 | Fangcang shelter hospitals: a novel concept for responding to public health emergencies Hit paper breakdown → | 2020 | 550 |
| 10 | Prevalence, risk factors, and management of asthma in China: a national cross-sectional study Hit paper breakdown → | 2019 | 540 |
| 11 | The Lancet Commission on lessons for the future from the COVID-19 pandemic Hit paper breakdown → | 2022 | 480 |
| 12 | Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD Hit paper breakdown → | 2020 | 469 |
| 13 | Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms Hit paper breakdown → | 2021 | 425 |
| 14 | 1998 | 335 | |
| 15 | Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial Hit paper breakdown → | 2018 | 286 |
| 16 | 2008 | 277 | |
| 17 | 2008 | 266 | |
| 18 | 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Hit paper breakdown → | 2023 | 253 |
| 19 | 2014 | 248 | |
| 20 | 2020 | 198 |
About Chen Wang
Chen Wang is a scholar working on Pulmonary and Respiratory Medicine, Physiology, Infectious Diseases, Neurology and Epidemiology, having authored 571 papers that have together received 31.1k indexed citations. Recurring topics across this work include Chronic Obstructive Pulmonary Disease (COPD) Research (82 papers), Pulmonary Hypertension Research and Treatments (55 papers), Respiratory Support and Mechanisms (34 papers), Smoking Behavior and Cessation (27 papers), COVID-19 Clinical Research Studies (26 papers), Asthma and respiratory diseases (24 papers), SARS-CoV-2 and COVID-19 Research (20 papers) and Long-Term Effects of COVID-19 (13 papers). The work is most often cited by research in Infectious Diseases (8.8k citations), Modeling and Simulation (1.5k citations), Pulmonary and Respiratory Medicine (6.8k citations), Neurology (3.0k citations) and Internal Medicine (438 citations). Chen Wang has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Peter Horby, George Fu Gao, Frederick G. Hayden, Simiao Chen, Till Bärnighausen, Juntao Yang, Weizhong Yang, Hua “Linda” Cai, Martin R. Wilkins and Pavel Jansa. Their work appears in journals such as The Lancet, CHEST Journal, International Journal of COPD, European Respiratory Journal and Respiratory Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.